STOCKWATCH: Alien invasions and base behavior in genomics
This article was originally published in Scrip
In the past few days it has become clear that the original $118 million bid for Californian genome sequencing firm Complete Genomics by China's BGI-Shenzhen was trumped by a $124 million bid from another US sequencing technology company Illumina. The higher bid was subsequently rejected by the Complete Genomics board, possibly because the company did not want to risk the use of a $30 million bridging loan that followed the signing of the merger agreement. Complete Genomics has argued in its SEC filings that the unsolicited offer from Illumina did not constitute ‘a Superior Proposal’ to BGI’s offer despite being worth 5% more because “among other reasons, there is a substantial likelihood that any transaction […] would fail to receive antitrust clearance.”
You may also be interested in...
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?